Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLO-CTO: Evolocumab in CTO After PCI
NCT05623995Phase 4Recruiting
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab in Chronic total occlusion of the coronary artery (CTO), coronary artery disease (CAD). Started Dec 2022; status: recruiting.
02
Drugs
evolocumab
03
Conditions
Chronic total occlusion of the coronary artery (CTO)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05623995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623995.